Co-infection of HIV and HCV Among Patients Under Antiretroviral Treatment: Insights from Selected Healthcare Facilities in Ilorin, Nigeria - Scorecard - MDSpire
Advertisement
Co-infection of HIV and HCV Among Patients Under Antiretroviral Treatment: Insights from Selected Healthcare Facilities in Ilorin, Nigeria
Clinical Scorecard: Co-infection of HIV and HCV Among Patients Under Antiretroviral Treatment: Insights from Selected Healthcare Facilities in Ilorin, Nigeria
At a Glance
Category
Detail
Condition
HIV/HCV co-infection
Key Mechanisms
Shared routes of transmission, immune dysfunction, and cytokine production leading to enhanced replication and liver damage.
Target Population
People living with HIV (PLHIV) in Ilorin, Nigeria.
Care Setting
Public secondary care hospitals in Ilorin, Kwara State, Nigeria.
Key Highlights
6.2% of PLHIV globally are co-infected with HCV.
HIV/HCV co-infection leads to higher mortality rates from liver disease.
Routine HCV screening is crucial for early detection in PLHIV.
National guidelines in Nigeria recommend HCV screening for PLHIV initiating ART.
Variability in co-infection prevalence reported across different regions in Nigeria.
Guideline-Based Recommendations
Diagnosis
Conduct rapid diagnostic screening for HCV antibodies in PLHIV.
Management
Implement National HIV Treatment guidelines for HCV screening among PLHIV.
Monitoring & Follow-up
Monitor for ART-related hepatotoxicity in co-infected patients.
Risks
Increased risk of liver disease progression and ART-related complications.
Patient & Prescribing Data
Adult PLHIV aged 18 to 70 years on ART for more than 6 months.
Co-infected patients may experience reduced CD4-cell recovery and higher hepatotoxicity.
Clinical Best Practices
Regular screening for HCV in PLHIV to prevent late-stage liver disease.
Adherence to ART while monitoring for potential hepatotoxic effects.
Educate patients on preventive measures against HCV transmission.
